Pharm Sci Seminar – Herman Sintim
Chronic myeloid leukemia, CML, is driven by ABL1 and the introduction of highly effective kinase inhibitors, such as imatinib, has resulted in a 5-year survival rate for CML to approach 90%.
Stay up-to-date with the latest events, including faculty presentations, career events for students and alumni, and so much more.
Chronic myeloid leukemia, CML, is driven by ABL1 and the introduction of highly effective kinase inhibitors, such as imatinib, has resulted in a 5-year survival rate for CML to approach 90%.